SSXB6 Inhibitors
SSXB6 inhibitors are a class of chemical compounds which are characterized by their selective inhibition of a specific biological target, typically a protein or enzyme identified by the acronym SSXB6. The exact nature of SSXB6 is often grounded in cellular biochemistry and molecular biology, where its role is critical in the regulation of certain biochemical pathways. The design of SSXB6 inhibitors is a sophisticated process that involves a deep understanding of the structure and function of the target, which is achieved through various scientific techniques such as X-ray crystallography, computational modeling, and structure-activity relationship (SAR) studies. These inhibitors are engineered to bind to the active site or another relevant domain of the SSXB6 protein, thereby altering its natural activity. The binding is usually highly specific, ensuring that the inhibitor interacts predominantly with the SSXB6 target, which reduces the likelihood of off-target effects that could interfere with the functions of other proteins.
In terms of chemical composition, SSXB6 inhibitors can vary widely, encompassing a range of small molecules, peptides, or even antibody-based molecules, depending on the nature of the target and the desired specificity and binding affinity. The design of these molecules takes into account factors such as the inhibitor's stability, solubility, and its ability to traverse cellular membranes, if necessary. These properties are optimized to ensure that the inhibitor can reach the target location within a biological system effectively. The development of SSXB6 inhibitors also involves iterative testing and refinement, where initial 'hit' compounds identified through high-throughput screening are modified to enhance their target interaction and pharmacokinetic profiles. Advanced techniques like medicinal chemistry, combinatorial chemistry, and parallel synthesis play a pivotal role in this optimization process. Through these methods, the inhibitors are honed to achieve maximal interaction with the SSXB6 protein, thus affecting its activity as intended by the design.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. If SSXB6 is a downstream effector of EGFR signaling, the inhibition of EGFR could lead to the downregulation of SSXB6 activity by reducing the phosphorylation events that activate downstream signaling proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTOR signaling pathway, which is involved in protein synthesis and cell growth. If SSXB6 activity is upregulated by mTOR-dependent pathways, inhibition by rapamycin would decrease SSXB6's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It prevents the activation of MAPKs, which are involved in stress and inflammatory responses. If SSXB6 is regulated through p38 MAPK signaling, then SB203580 would indirectly inhibit SSXB6 by blocking this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway, important for cell survival and proliferation. If SSXB6 functions downstream of PI3K, then LY294002 would inhibit SSXB6 by preventing pathway activation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that changes the chromatin structure and affects gene expression. If the gene expression of SSXB6 is regulated by acetylation status, then Trichostatin A could reduce SSXB6 activity by altering its expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins tagged for destruction. If SSXB6 is regulated by proteasomal degradation, bortezomib could indirectly increase SSXB6 levels, but excessive accumulation might lead to functional inhibition due to aggregation or misfolding. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, which is implicated in cell proliferation and differentiation. If SSXB6 activity is modulated by the ERK pathway, PD98059 would result in decreased SSXB6 activity by inhibiting this pathway. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis in the endoplasmic reticulum. If SSXB6 activity is calcium-dependent, thapsigargin could inhibit SSXB6 by altering calcium signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that impedes the MAPK/ERK pathway. Similar to PD98059, if SSXB6 is regulated by ERK signaling, the use of U0126 would lead to a reduction in SSXB6 activity. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective inhibitor of mutant forms of EGFR that are resistant to first-generation inhibitors. If SSXB6 is activated by such mutant EGFRs, WZ4002 could decrease SSXB6 activity by specifically targeting abnormal signaling. | ||||||